Phosphoproteomic profiling of EGFR-mutant lung adenocarcinoma identifies specific phosphorylation events, such as EGFR-pTyr1197, MAPK7-pTyr221, and DAPP1-pTyr139, that serve as quantitative biomarkers of TKI sensitivity, with their inhibition dynamics directly correlating with drug response, offering real-time pharmacodynamic insights (111). This evidence concerns the gene EGFR and lung adenocarcinoma.